Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer

21MO - Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC


03 Dec 2022


Mini Oral session: Breast cancer


Tumour Site

Breast Cancer


Zhimin Shao


Annals of Oncology (2022) 33 (suppl_9): S1438-S1440. 10.1016/annonc/annonc1120


Z. Shao1, Q. Liu2, Z. Tong3, W. Li4, L. Cai5, Y. Bai6, K. Amin7, P. Deshpande8, Y. Bi6, B. Xu9

Author affiliations

  • 1 Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 - Guangzhou/CN
  • 3 Department Of Breast Cancer Pathology, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN
  • 4 Oncology, The First Bethune Hospital of Jilin University, 130021 - Changchun/CN
  • 5 Oncology, Harbin Medical University Cancer Hospital, 150040 - Harbin/CN
  • 6 Medical Department, Novartis Global Drug Development, 102299 - Beijing/CN
  • 7 Research & Development, Novartis, 4056 - Basel/CH
  • 8 Oncology, Novartis, 07936 - East Hanover/US
  • 9 Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Collegeital, 100021 - Beijing/CN


Login to access the resources on OncologyPRO.

Abstract 21MO


MONALEESA (ML)-2 and -7 enrolled postmenopausal (postM) and premenopausal (preM) patients (pts) with HR+/HER2− ABC, respectively, to initial RIB + ET treatment. Both demonstrated a statistically significant PFS and OS benefit in the ITT populations, with similar trends in the Asian subgroups. Specifically, regarding PFS in the Asian subgroups, RIB + ET had an HR of 0.39 (0.17-0.91) in ML-2 (n=51; median follow-up 15.3 mo) and ET had an HR of 0.40 (0.26-0.63) in ML-7 (n=198; median follow-up 19.2 mo). Here we report the primary results of a phase II bridging study of initial ET ± RIB in postM and preM pts from mainland China with HR+/HER2– ABC.


Pts were randomized 1:1; postM received letrozole (LET) + RIB or placebo (PBO) and preM received NSAI + goserelin + RIB or PBO. Primary endpoint was PFS (local assessment based on RECIST 1.1 criteria). The study was not powered to show statistical significance; it was adequately sized to show consistency of PFS of RIB + ET vs ET in Chinese populations compared to ML-2 and ML-7. Secondary endpoints included PK, OS, ORR, and safety.


As of 15 April 2022, 77 and 77 postM pts and 79 and 77 preM pts were treated with RIB or PBO, respectively. Median follow-up was 34.7 mo for both groups. Baseline characteristics were generally balanced between arms within the cohorts. In the postM cohort, mPFS was not reached with RIB vs 18.5 mo with PBO (HR 0.400; 95% CI 0.258-0.618). In the preM cohort, the median PFS was 27.6 vs 14.7 mo (HR 0.672; 95% CI 0.448-1.009) for RIB vs PBO. ORR was higher for RIB in both postM and preM pts (Table); OS was not mature. The adverse event profile was consistent with what is known for ET ± RIB; the tolerability is consistent with ML-2 and -7 with no new findings.


Along with the results of the ML studies, this bridging study demonstrates the consistent efficacy benefit and well-tolerated safety profile of RIB + ET in Chinese pts. Table: 21MO

Parameter PostM PreM
RIB + LET n=77 PBO + LET n=77 RIB + NSAI + goserelin n=79 PBO + NSAI + goserelin n=77
Treatment ongoing, n 35 11 27 14
PFS, median, mo Not reached 18.5 27.6 14.7
HR (95% CI) 0.400 (0.258-0.618) 0.672 (0.448-1.009)
ORR, % (95% CI)a 60.3 (48.1-71.5) 49.3 (37.2-61.4) 53.6 (41.2-65.7) 38.5 (26.7-51.4)

aMeasurable disease.

Clinical trial identification


Editorial acknowledgement

Medical writing support was provided by Chris Carter at MediTech Media, funded by Novartis Pharmaceuticals Corporation.

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation.


Novartis Pharmaceuticals Corporation.


Y. Bai, K. Amin, P. Deshpande, Y. Bi: Financial Interests, Personal, Full or part-time Employment: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.